TargetBeta
LYN
LYN proto-oncogene, Src family tyrosine kinase · also JTK8 · SH2 domain containing
1 program in company-led studies act on LYN, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 127 running | BTK | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Purpura, Thrombocytopenic, Idiopathic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 23, 2026birelentinib · Dizal Pharmaceuticals · phase 3 · NCT07888569
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.